相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Vedolizumab or Tumor Necrosis Factor Antagonist Use and Risk of New or Recurrent Cancer in Patients With Inflammatory Bowel Disease With Prior Malianancy: A Retrospective Cohort Study
Amar Vedamurthy et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2022)
AGA Technical Review on the Medical Management of Moderate to Severe Luminal and Perianal Fistulizing Crohn's Disease
Siddharth Singh et al.
GASTROENTEROLOGY (2021)
IM-UNITI: Three-year Efficacy, Safety, and Immunogenicity of Ustekinumab Treatment of Crohn's Disease
Stephen B. Hanauer et al.
JOURNAL OF CROHNS & COLITIS (2020)
P729 The SAPPHIRE registry: Safety of immunosuppression in a prospective cohort of inflammatory bowel disease patients with a HIstoRy of CancEr
J Axelrad et al.
Journal of Crohns & Colitis (2020)
Efficacy and safety of simultaneous treatment with two biologic medications in refractory Crohn's disease
Edward Yang et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2020)
Ustekinumab as Induction and Maintenance Therapy for Ulcerative Colitis
B. E. Sands et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
ACG Clinical Guideline: Ulcerative Colitis in Adults
David T. Rubin et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2019)
The safety of vedolizumab for ulcerative colitis and Crohn's disease
Jean-Frederic Colombel et al.
GUT (2017)
Risk of Malignancy in a Nationwide Cohort of Elderly Inflammatory Bowel Disease Patients
Nabeel Khan et al.
DRUGS & AGING (2017)
Risk of New or Recurrent Cancer in Patients With Inflammatory Bowel Disease and Previous Cancer Exposed to Immunosuppressive and Anti-Tumor Necrosis Factor Agents
Jordan Axelrad et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2016)
Cancer Recurrence Following Immune-Suppressive Therapies in Patients With Immune-Mediated Diseases: A Systematic Review and Meta-analysis
Edward Shelton et al.
GASTROENTEROLOGY (2016)
First Do No Harm: Is It Safe to Use Immunosuppressants in Inflammatory Bowel Disease Patients With Prior Cancer?
Geoffrey C. Nguyen
GASTROENTEROLOGY (2016)
Ustekinumab as Induction and Maintenance Therapy for Crohn's Disease
B. G. Feagan et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
European Evidence-based Consensus: Inflammatory Bowel Disease and Malignancies
Vito Annese et al.
JOURNAL OF CROHNS & COLITIS (2015)
Risk of new or recurrent cancer under immunosuppressive therapy in patients with IBD and previous cancer
Laurent Beaugerie et al.
GUT (2014)
Impact of the diagnosis and treatment of cancer on the course of inflammatory bowel disease
S. Rajca et al.
JOURNAL OF CROHNS & COLITIS (2014)
The management of immunosuppression in patients with inflammatory bowel disease and cancer
Oren Bernheim et al.
GUT (2013)
Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis
Brian G. Feagan et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease
William J. Sandborn et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Effects of Cancer Treatment on Inflammatory Bowel Disease Remission and Reactivation
Jordan E. Axelrad et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2012)
Risk of Melanoma and Nonmelanoma Skin Cancer Among Patients With Inflammatory Bowel Disease
Millie D. Long et al.
GASTROENTEROLOGY (2012)
Increased Risk for Nonmelanoma Skin Cancers in Patients Who Receive Thiopurines for Inflammatory Bowel Disease
Laurent Peyrin-Biroulet et al.
GASTROENTEROLOGY (2011)
Increased Risk for Non-Melanoma Skin Cancer in Patients With Inflammatory Bowel Disease
Millie D. Long et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2010)
Increased risk of lymphoma among inflammatory bowel disease patients treated with azathioprine and 6-mercaptopurine
A Kandiel et al.
GUT (2005)
Increased incidence of non-Hodgkin's lymphoma in inflammatory bowel disease patients on immunosuppressive therapy but overall risk is low
RJ Farrell et al.
GUT (2000)
分享论文
